The 2026 Spring Festival travel rush begins on February 2 and will run for 40 days, ending on March 13. Ahead of this annual migration, CGTN published a feature article exploring how the event has transcended its role as a transport phenomenon, becoming a unique lens through which to view China’s social transformation. BEIJING, Feb. […]
South Africa
BHP backs the next wave of exploration and technology talent in its biggest Xplor intake yet
MELBOURNE, Australia, Feb. 01, 2026 (GLOBE NEWSWIRE) — BHP has selected 10 early-stage exploration and technology companies for the 2026 BHP Xplor program, marking the largest cohort since the program began and its fourth year of operation. The 2026 cohort brings together junior exploration companies, geoscience organisations, and technology teams that collectively span the discovery […]
BHP backs the next wave of exploration and technology talent in its biggest Xplor intake yet
MELBOURNE, Australia, Feb. 01, 2026 (GLOBE NEWSWIRE) — BHP has selected 10 early-stage exploration and technology companies for the 2026 BHP Xplor program, marking the largest cohort since the program began and its fourth year of operation. The 2026 cohort brings together junior exploration companies, geoscience organisations, and technology teams that collectively span the discovery […]
Details on the timetable of the simplified tender offer on North Atlantic Energies shares
Paris, Jan. 30, 2026 (GLOBE NEWSWIRE) — NORTH ATLANTIC ENERGIES Details on the timetable of the simplified tender offer on North Atlantic Energies shares Paris, FRANCE – January 30, 2026 – North Atlantic France SAS (“North Atlantic France”) refers to its acquisition from ExxonMobil France Holding SAS (“ExxonMobil”) of ExxonMobil’s entire stake in North Atlantic Energies […]
Kyowa Kirin to Regain Control of Rocatinlimab Development and Commercialization Program, Demonstrating Strong Commitment to Address High Unmet Medical Need in Atopic Dermatitis
Kyowa Kirin affirms commitment to developing rocatinlimab as a life-changing differentiated asset with significant market potential. Rocatinlimab’s novel approach as an investigational T-cell rebalancing therapy directly targeting the OX40 receptor expressed on pathogenic T-cells shows potential to deliver long-term disease control in patients with moderate-to-severe atopic dermatitis (msAD). Regulatory submission is planned in the first […]